Jones Taff, Allard Francine, Cyr Sonya L, Tran Steven P, Plante Martin, Gauthier Joelle, Bellerose Nathalie, Lowell George H, Burt David S
ID Biomedical Corporation of Quebec, 7150 Frederick Banting, Suite 200, Ville Saint-Laurent, Montreal, Que., Canada H4S 2A1.
Vaccine. 2003 Sep 8;21(25-26):3706-12. doi: 10.1016/s0264-410x(03)00387-6.
The potential for enhancing the immunogenicity of recombinant (baculovirus-derived) influenza hemagglutinin (rHA) was investigated by comparing the immune responses elicited in mice by an intranasal (i.n.) rHA formulated with Proteosomes, with those induced by intramuscular (i.m.) or i.n. rHA alone. The Proteosome-rHA vaccine induced mucosal responses in the respiratory tract, as well as high serum IgG and hemagglutination inhibition (HAI) titers. In contrast, rHA alone given i.m. induced serum IgG without mucosal responses and was ineffective at inducing either mucosal or systemic responses when given i.n. Only mice immunized with the Proteosome-rHA vaccine were completely protected from both death and acute morbidity following live virus challenge, indicating that the i.n. Proteosome-rHA vaccine induced more complete protective immunity than the same doses of unformulated rHA given i.n. or i.m.
通过比较用蛋白酶体配制的鼻内（i.n.）重组（杆状病毒衍生）流感血凝素（rHA）在小鼠中引发的免疫反应与单独肌肉内（i.m.）或鼻内rHA诱导的免疫反应，研究了增强重组（杆状病毒衍生）流感血凝素（rHA）免疫原性的潜力。蛋白酶体-rHA疫苗在呼吸道诱导了黏膜反应，以及高血清IgG和血凝抑制（HAI）滴度。相比之下，单独肌肉注射rHA诱导了血清IgG但无黏膜反应，而鼻内给药时在诱导黏膜或全身反应方面无效。只有用蛋白酶体-rHA疫苗免疫的小鼠在活病毒攻击后完全免受死亡和急性发病的影响，这表明鼻内蛋白酶体-rHA疫苗比相同剂量的未配制鼻内或肌肉注射rHA诱导了更完全的保护性免疫。
